Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-cash Items (2016 - 2025)

Regenxbio has reported Non-cash Items over the past 12 years, most recently at $17.5 million for Q4 2025.

  • Quarterly results put Non-cash Items at $17.5 million for Q4 2025, up 7201.25% from a year ago — trailing twelve months through Dec 2025 was $17.5 million (up 7201.25% YoY), and the annual figure for FY2025 was $17.5 million, up 7201.25%.
  • Non-cash Items for Q4 2025 was $17.5 million at Regenxbio, up from $7.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for RGNX hit a ceiling of $64.5 million in Q2 2021 and a floor of $84000.0 in Q1 2025.
  • Median Non-cash Items over the past 5 years was $8.8 million (2023), compared with a mean of $14.7 million.
  • Peak annual rise in Non-cash Items hit 7201.25% in 2025, while the deepest fall reached 99.33% in 2025.
  • Regenxbio's Non-cash Items stood at $41.1 million in 2021, then crashed by 61.62% to $15.8 million in 2022, then tumbled by 55.58% to $7.0 million in 2023, then plummeted by 96.58% to $240000.0 in 2024, then surged by 7201.25% to $17.5 million in 2025.
  • The last three reported values for Non-cash Items were $17.5 million (Q4 2025), $7.7 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.